FERNANDINA BEACH, FL – Precision medication safety organization GalenusRx welcomes Stephanie Davis, a top-ranked healthcare equity research analyst, to its distinguished advisory board.
Davis brings a background covering a range of health sectors, including healthcare technology, retail pharmacy, consumer health, drug distributors, and labs. Most recently, she led the Healthcare Technology & Distribution research team at Barclays. Prior, she directed coverage of the sector at SVB Securities, Citibank, and J.P. Morgan.
That breadth makes Davis a valuable addition to the GalenusRx advisory board, a growing team of experts who specialize in every aspect of the healthcare industry, from patient care to operational performance.
“To make real change in healthcare, you need to balance bold vision with a concrete foundation, from science and technology to finance,” said Calvin H. Knowlton, PhD, Co-CEO and Executive Chairman, GalenusRx. “Stephanie Davis sees the full picture and grasps healthcare financial analysis and strategy in a way few people do. We’re fortunate to benefit from her expertise.”
A Columbia University alum and CFA charterholder, Davis is well-known and well-respected across the industry, having been featured in The Wall Street Journal, The Economist, and Bloomberg, among other top publications.
“Success for a healthcare organization requires not just doing well, but also doing good. I believe GalenusRx is poised to do both,” Davis said. ” Their technology has the potential to improve patient outcomes by guiding people to safer, more effective medication choices all while driving cost savings across health systems, ACOs, pharma, and the patient’s own wallet. It’s a strong combination of clinical impact and financial value, and I’m excited to help the business execute on this opportunity.”
